Abstract
BackgroundThe aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD).MethodsThirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n = 15) or EMD (control, n = 15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability.ResultsBoth treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33 ± 1.58 mm in the A-PRF+ group, respectively 2.60 ± 1.18 mm in the EMD group (p < 0.001).ConclusionWithin the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD during surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing.Clinical Relevance A-PRF+ may be suitable for the treatment of intrabony periodontal defects.Trial registration number (TRN) NCT04404374 (ClinicalTrials.gov ID).
Highlights
The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-Platelet-Rich Fibrin’clot’ (PRF)+) respect to enamel matrix derivative (EMD)
Clinical Relevance Advanced Platelet Rich Fibrin (A-PRF)+ may be suitable for the treatment of intrabony periodontal defects
Post-hoc power calculations for betweengroups comparison of pocket depth (PD) and bone sounding (BS) values were not estimable because the two group means at 6 months were identical
Summary
The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD). The main goal of the comprehensive periodontal treatment is to eliminate inflammation and to prevent further destruction of the periodontium, as well as to achieve sustainable condition in the long-term [1]. Only a few factors have reached clinical evaluation, earlier research objectives expected only to achieve the optimal dosage and the combination of growth and differentiation factors [5]. Data from long-term follow-up clinical studies demonstrated that treatment of deep periodontal intrabony defects with EMD resulted in a significant increase of clinical attachment gain and bone fill compared to’open flap debridement’ [6,7,8,9]. Introduction of autologous platelet concentrates (Platelet-Rich Plasma—PRP, Platelet-Rich Gel—PRG, Platelet-Rich Fibrin—PRF) presents a new period in periodontal application of chemical-biological factors [10,11,12,13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
